Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through &lt;18 years of age: A randomized controlled phase II dose-finding trial

Chang, Lee-Jah; Anderson, Evan J.; Jeanfreau, Robert; He, Ying; Hicks, Bryony; Shrestha, Anju; Pandey, Aseem; Landolfi, Victoria; DeBruijn, Iris

doi:10.1016/j.vaccine.2021.02.014

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were no documented fatalities or major adverse effects linked to the treatment. Thus, IIV4-HD is more immunogenic in comparison to IIV4-SD and has the same safety profile [54].…”

Section: Immunogenicity and Safety Of Different Types Of Influenza Va...mentioning

confidence: 99%

Unlocking the Power of Influenza Vaccines for Pediatric Population: A Narrative Review

Albalawi,

Alhassun,

Almarshud

et al. 2024

Cureus

View full text Add to dashboard Cite

The flu, often known as influenza, is a dangerous public health hazard for the pediatric population. Immunization is essential for decreasing the burden of the disease and avoiding complications related to influenza. However, the immunogenicity, efficacy, and safety of different influenza vaccines in children warrant careful evaluation.The purpose of this narrative review is to give a summary of the existing literature on the immunogenicity, efficacy, and safety of several vaccinations against influenza viruses in children. The review incorporates evidence from a range of studies focusing on the outcomes of interest. Immunogenicity studies have shown that influenza vaccines induce a robust immune response in children, primarily through neutralizing antibodies' formation. However, variations in vaccine composition influence the duration and magnitude of immune responses. Safety is a crucial consideration in pediatric vaccination. In children, influenza vaccinations have generally shown a high safety profile, with mild and temporary side effects being the most common. Vaccinations against influenza have shown a modest level of efficacy in avoiding hospitalizations linked to influenza, laboratory-confirmed influenza infections, and serious consequences in children. Live attenuated vaccines have shown higher effectiveness against matched strains compared to inactivated vaccines. In conclusion, this narrative review highlights that receiving influenza vaccination in children aged six to 47 months is very important. While different vaccines exhibit varying immunogenicity, safety profiles, and effectiveness, they all contribute to reducing the burden of influenza among children. Future research should focus on optimizing vaccine strategies, improving vaccine coverage, and evaluating longterm protection.

show abstract

“…There were no documented fatalities or major adverse effects linked to the treatment. Thus, IIV4-HD is more immunogenic in comparison to IIV4-SD and has the same safety profile [54].…”

Section: Immunogenicity and Safety Of Different Types Of Influenza Va...mentioning

confidence: 99%

Unlocking the Power of Influenza Vaccines for Pediatric Population: A Narrative Review

Albalawi,

Alhassun,

Almarshud

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Therefore, as adults 65 years and older are at higher risk of influenza complications, the ACIP recommends that adults at least 65 years receive either a HD-IIV or a MF59-adjuvanted standard-dose egg-based vaccine (aIIV4) [5 ▪▪ ]. In a pediatric phase II randomized controlled trial (RCT), HD-IIV4 was found to be safe, well tolerated, and induced a higher hemagglutinin inhibition and seroneutralization antibody titers compared with SD-IIV, especially in children 6 months through less than 3 years [19]. Likewise, some studies have shown that HD-IIV, produce a more robust immune response in certain immunocompromised patients compared with SD-IIV [20 ▪ ,21,22].…”

Section: Available Vaccinesmentioning

confidence: 99%

Influenza vaccines: where we are, where we are going

Khalil

Bernstein

2022

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of reviewInfluenza vaccines are the most useful strategy for preventing influenza illness, especially in the setting of the COVID-19 pandemic. For the coming year (2021/2022) all vaccines will be quadrivalent and contain two influenza A strains [(H1N1)pdm09-like and (H3N2)-like viruses] and two influenza B strains (Victoria lineage-like and Yamagata lineage-like viruses). However, the currently licensed have suboptimal efficacy due to the emergence of new strains and vaccine production limitations. In this review, we summarize the current recommendations as well as new advancements in influenza vaccinations.Recent findingsRecent advances have been aimed at moving away from egg-based vaccines and toward cell culture and recombinant vaccines. This removes egg adaptations that decrease vaccine efficacy, removes the reliance on egg availability and decreases the time necessary to manufacture vaccines. However, even more radical changes are needed if we are to reach the ultimate goal of a universal vaccine capable of providing long-lasting protection against all or at least most influenza strains. We discuss various strategies, including using more stable influenza antigens such as the hemagglutinin stalk and internal proteins as well as new adjuvants, new vaccine formulations, and DNA/RNA-based vaccines that are currently being developed.SummaryThe currently available vaccines have suboptimal efficacy and do not provide adequate protection against drifted and shifted strains. Thus, the development of a universal influenza vaccine that induces long-lasing immunity and protects against a broad range of strains is crucial.

show abstract

“…Un recentissimo studio, pubblicato nel 2021 da Chang et al [ 37 ] ha riportato il dato di immunogenicità assoluta riferito al vaccino QIVe all’interno di uno studio di confronto con il vaccino quadrivalente inattivato high-dose (QIVe-HD), somministrato in una o due dosi, a tre dosaggi differenti in bambini di età compresa tra 6 mesi e < 18 anni. Lo studio è stato condotto tra il 9 ottobre 2018 e il 18 marzo 2019 e sono stati arruolati e randomizzati 665 partecipanti di cui 661 vaccinati in precedenza.…”

Section: Immunogenicità Efficacia Teorica E Sul Campounclassified

“…Nello studio di Chang et al [ 37 ] è stata confrontata la sicurezza di QIVe-HD (high dose) con un QIVe (standard-dose), nella fascia d’età tra 6 mesi e < 18 anni. La reattogenicità (reazioni sollecitate al sito di iniezione e reazioni sistemiche sollecitate) è risultata leggermente superiore per QIVe-HD rispetto a QIVe.…”

Section: Sicurezza E Tollerabilitàunclassified

Journal of Preventive Medicine and Hygiene, Vol. 62 No. 2s1 (2021): Health Technology Assessment (HTA) dell’introduzione della vaccinazione antinfluenzale per la popolazione giovanile italiana con il vaccino Fluenz Tetra®

Boccalini

Pariani

Calabrò

et al. 2021

View full text Add to dashboard Cite

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial

Cited by 4 publications

References 24 publications

Unlocking the Power of Influenza Vaccines for Pediatric Population: A Narrative Review

Unlocking the Power of Influenza Vaccines for Pediatric Population: A Narrative Review

Influenza vaccines: where we are, where we are going

Journal of Preventive Medicine and Hygiene, Vol. 62 No. 2s1 (2021): Health Technology Assessment (HTA) dell’introduzione della vaccinazione antinfluenzale per la popolazione giovanile italiana con il vaccino Fluenz Tetra®

Contact Info

Product

Resources

About

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial

Cited by 4 publications

References 24 publications

Unlocking the Power of Influenza Vaccines for Pediatric Population: A Narrative Review

Unlocking the Power of Influenza Vaccines for Pediatric Population: A Narrative Review

Influenza vaccines: where we are, where we are going

Journal of Preventive Medicine and Hygiene, Vol. 62 No. 2s1 (2021): Health Technology Assessment (HTA) dell’introduzione della vaccinazione antinfluenzale per la popolazione giovanile italiana con il vaccino Fluenz Tetra®

Contact Info

Product

Resources

About

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial